The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece
Abstract In light of the accumulating evidence for survival benefit coming from the use of macrolides for community-acquired pneumonia (CAP), a group of experts from the field of internal medicine and infectious diseases frame a position statement on the use of macrolides for the management of bacterial CAP and for infection by the novel coronavirus (COVID-19). The statement is framed taking into consideration existing publications and own research experience. The main content of this statement is that the combination of one β-lactam and a macrolide should be the first treatment of choice for patients with severe bacterial CAP. Severity is assessed as scoring 2 or more points on the CURB65 scoring system of severity or as pneumonia severity index III to V or C-reactive protein more than 150 mg/l; the suggested macrolide is either azithromycin or clarithromycin. The experts also suggest that in COVID-19 pneumonia, the combination of one β-lactam and a macrolide should be reserved only when there is strong suspicion of bacterial co-infection..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Infectious diseases and therapy - 10(2021), 3 vom: 16. Juni, Seite 1081-1095 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Giamarellos-Bourboulis, Evangelos J. [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Azithromycin |
---|
Anmerkungen: |
© The Author(s) 2021 |
---|
doi: |
10.1007/s40121-021-00471-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR044699565 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | SPR044699565 | ||
003 | DE-627 | ||
005 | 20230519231600.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210730s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40121-021-00471-1 |2 doi | |
035 | |a (DE-627)SPR044699565 | ||
035 | |a (SPR)s40121-021-00471-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
082 | 0 | 4 | |a 610 |q ASE |
100 | 1 | |a Giamarellos-Bourboulis, Evangelos J. |e verfasserin |4 aut | |
245 | 1 | 4 | |a The Role of Macrolides for the Management of Community-Acquired Pneumonia and Pneumonia by the Novel Coronavirus SARS-CoV-2 (COVID-19): A Position Paper by Four Medical Societies from Greece |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2021 | ||
520 | |a Abstract In light of the accumulating evidence for survival benefit coming from the use of macrolides for community-acquired pneumonia (CAP), a group of experts from the field of internal medicine and infectious diseases frame a position statement on the use of macrolides for the management of bacterial CAP and for infection by the novel coronavirus (COVID-19). The statement is framed taking into consideration existing publications and own research experience. The main content of this statement is that the combination of one β-lactam and a macrolide should be the first treatment of choice for patients with severe bacterial CAP. Severity is assessed as scoring 2 or more points on the CURB65 scoring system of severity or as pneumonia severity index III to V or C-reactive protein more than 150 mg/l; the suggested macrolide is either azithromycin or clarithromycin. The experts also suggest that in COVID-19 pneumonia, the combination of one β-lactam and a macrolide should be reserved only when there is strong suspicion of bacterial co-infection. | ||
650 | 4 | |a Community-acquired pneumonia |7 (dpeaa)DE-He213 | |
650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
650 | 4 | |a Azithromycin |7 (dpeaa)DE-He213 | |
650 | 4 | |a Clarithromycin |7 (dpeaa)DE-He213 | |
650 | 4 | |a Immunomodulation |7 (dpeaa)DE-He213 | |
700 | 1 | |a Daikos, George L. |e verfasserin |4 aut | |
700 | 1 | |a Gargalianos, Panagiotis |e verfasserin |4 aut | |
700 | 1 | |a Gogos, Charalambos |e verfasserin |4 aut | |
700 | 1 | |a Lazanas, Marios |e verfasserin |4 aut | |
700 | 1 | |a Panagopoulos, Periklis |e verfasserin |4 aut | |
700 | 1 | |a Poulakou, Garyphallia |e verfasserin |4 aut | |
700 | 1 | |a Sambatakou, Helen |e verfasserin |4 aut | |
700 | 1 | |a Samarkos, Michael |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Infectious diseases and therapy |d Heidelberg : Springer, 2012 |g 10(2021), 3 vom: 16. Juni, Seite 1081-1095 |w (DE-627)SPR032878133 |w (DE-600)2701611-0 |x 2193-6382 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2021 |g number:3 |g day:16 |g month:06 |g pages:1081-1095 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40121-021-00471-1 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
912 | |a SSG-OLC-PHA | ||
951 | |a AR | ||
952 | |d 10 |j 2021 |e 3 |b 16 |c 06 |h 1081-1095 |